Logo image of RDHL

REDHILL BIOPHARMA LTD-SP ADR (RDHL) Stock Fundamental Analysis

USA - NASDAQ:RDHL - US7574683014 - ADR

1.67 USD
-0.02 (-1.18%)
Last: 9/22/2025, 9:01:33 PM
1.62 USD
-0.05 (-2.99%)
Pre-Market: 9/23/2025, 8:00:00 AM
Fundamental Rating

1

RDHL gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. RDHL has a bad profitability rating. Also its financial health evaluation is rather negative. RDHL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RDHL has reported negative net income.
RDHL had a negative operating cash flow in the past year.
RDHL had negative earnings in 4 of the past 5 years.
RDHL had a negative operating cash flow in each of the past 5 years.
RDHL Yearly Net Income VS EBIT VS OCF VS FCFRDHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

RDHL has a Return On Assets (-45.82%) which is in line with its industry peers.
Industry RankSector Rank
ROA -45.82%
ROE N/A
ROIC N/A
ROA(3y)4.28%
ROA(5y)-16.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RDHL Yearly ROA, ROE, ROICRDHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

With a decent Gross Margin value of 60.31%, RDHL is doing good in the industry, outperforming 67.86% of the companies in the same industry.
In the last couple of years the Gross Margin of RDHL has remained more or less at the same level.
RDHL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.56%
GM growth 5Y-1.2%
RDHL Yearly Profit, Operating, Gross MarginsRDHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

RDHL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RDHL has more shares outstanding
The number of shares outstanding for RDHL has been increased compared to 5 years ago.
RDHL has a better debt/assets ratio than last year.
RDHL Yearly Shares OutstandingRDHL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
RDHL Yearly Total Debt VS Total AssetsRDHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -35.00, we must say that RDHL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -35.00, RDHL is not doing good in the industry: 87.24% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -35
ROIC/WACCN/A
WACC8.29%
RDHL Yearly LT Debt VS Equity VS FCFRDHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

A Current Ratio of 0.54 indicates that RDHL may have some problems paying its short term obligations.
RDHL has a Current ratio of 0.54. This is amonst the worse of the industry: RDHL underperforms 92.35% of its industry peers.
A Quick Ratio of 0.37 indicates that RDHL may have some problems paying its short term obligations.
RDHL has a worse Quick ratio (0.37) than 92.35% of its industry peers.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.37
RDHL Yearly Current Assets VS Current LiabilitesRDHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for RDHL have decreased strongly by -100.30% in the last year.
Looking at the last year, RDHL shows a very strong growth in Revenue. The Revenue has grown by 23.17%.
RDHL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.04% yearly.
EPS 1Y (TTM)-100.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.3%
Revenue 1Y (TTM)23.17%
Revenue growth 3Y-54.57%
Revenue growth 5Y5.04%
Sales Q2Q%23.17%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 45.22% on average over the next years. This is a very strong growth
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year82.69%
Revenue Next 2Y55.97%
Revenue Next 3Y45.22%
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RDHL Yearly Revenue VS EstimatesRDHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
RDHL Yearly EPS VS EstimatesRDHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 -500 -1K -1.5K -2K -2.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RDHL. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RDHL Price Earnings VS Forward Price EarningsRDHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RDHL Per share dataRDHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

RDHL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REDHILL BIOPHARMA LTD-SP ADR

NASDAQ:RDHL (9/22/2025, 9:01:33 PM)

Premarket: 1.62 -0.05 (-2.99%)

1.67

-0.02 (-1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-16 2024-09-16
Earnings (Next)N/A N/A
Inst Owners4.3%
Inst Owner Change-45.8%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.83M
Analysts82.86
Price TargetN/A
Short Float %1335.54%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.76
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.09
FCFYN/A
OCF(TTM)-4.09
OCFYN/A
SpS3.51
BVpS-2.04
TBVpS-4.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.31%
FCFM N/A
ROA(3y)4.28%
ROA(5y)-16.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.56%
GM growth 5Y-1.2%
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.45%
Cap/Sales 0.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.37
Altman-Z -35
F-Score3
WACC8.29%
ROIC/WACCN/A
Cap/Depr(3y)1.49%
Cap/Depr(5y)123.93%
Cap/Sales(3y)0.2%
Cap/Sales(5y)16.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.3%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)23.17%
Revenue growth 3Y-54.57%
Revenue growth 5Y5.04%
Sales Q2Q%23.17%
Revenue Next Year82.69%
Revenue Next 2Y55.97%
Revenue Next 3Y45.22%
Revenue Next 5YN/A
EBIT growth 1Y-215.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.84%
OCF growth 3YN/A
OCF growth 5YN/A